Gross Margin % is calculated as gross profit divided by its revenue. SCYNEXIS's Gross Profit for the
three
months ended in Dec. 2023 was $-8.9 Mil. SCYNEXIS's Revenue for the
three
months ended in Dec. 2023 was $5.8 Mil. Therefore, SCYNEXIS's Gross Margin % for the quarter that ended in Dec. 2023 was -153.30%.
The historical rank and industry rank for SCYNEXIS's Gross Margin % or its related term are showing as below:
SCYX'
s Gross Margin % Range Over the Past 10 Years
Min: 87.66 Med: 93.24 Max: 284.87
Current: 88.85
During the past 12 years, the highestGross Margin % of SCYNEXIS was 284.87%. The lowest was 87.66%. And the median was 93.24%.
SCYX's Gross Margin % is ranked better than 96.77% of 990
companies
in the Drug Manufacturers industry
Industry Median: 46.8
vs SCYX: 88.85
SCYNEXIS had a gross margin of -153.30% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for SCYNEXIS was 0.00% per year.
SCYNEXIS Gross Margin % Historical Data
The historical data trend for SCYNEXIS's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SCYNEXIS's Gross Margin %
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS's Gross Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Gross Margin % distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
SCYNEXIS (NAS:SCYX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
SCYNEXIS had a gross margin of -153.30% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
SCYNEXIS Gross Margin % Related Terms
Thank you for viewing the detailed overview of SCYNEXIS's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your 